Diego Ezcurra

PROFILE

35 years of combined experience in advanced reproductive technologies (ART), humans and animals.

20 years managing my own ART business in South America, developed 5 successful laboratories in Advanced Reproductive Technologies and transferred more than 3000 embryos/year.

15 years of experience in human ART and Biopharmaceutical industry,  6 years in US and 9 years globally.

EXPERIENCE

Head of Global Customers and Fertility Technologies Excellence under Global

Fertility Franchise, Boston, Massachusetts.

Merck / EMD Serono S.A. – 2015-Up to date

Global Head of Fertility-ESA under R&D/GMA, Boston, Massachusetts.

Merck Serono / EMD Serono S.A. – 2011-2014

 Global Scientific Director Fertility, Geneva, Switzerland.

Merck Serono S.A. – 2008-2011

Medical Director for Fertility in USA.

EMD Serono S.A. – 2007-2008

Director of Medical Operations for Fertility and Endocrinology MSL’s.

Serono Inc. – 2006-2007                       

Manager of Fertility MSL’s , Medical Affairs Department, Rockland, USA.

Serono Inc. – 2003-2006

Medical Science Liaison North East, Medical Affairs Department, Rockland, USA.

Serono Inc. – 2002-2003

CEO and Technical Director of Ezcurra Transferencias Embrionarias, Argentina   

Ezcurra Transferencias Embrionarias S.A. – 1982-2002

EDUCATION 

Bachelor of Science

Colegio Champagnat, Buenos Aires, Argentina

Graduated 1975

Doctor in Veterinary Medicine

University of Buenos Aires, Argentina

Graduated 1982

Fellowship Residency in Animal Science Department

University of California Davis, USA

Completed 1990

 

Serono Leadership Course with 24 worldwide selected employees

Babson College – Boston, Valencia

Completed 2006

 

Master of Science in Human Embryology and Andrology

Eastern Virginia Medical School, USA, Graduated 2008

AFFILIATIONS

  •  International Embryo Transfer Association (1984)
  •  European Society Human Reproduction and Endocrinology, (2002)
  •  American Society Reproductive Medicine (2002)
  •  Embryology Society of New York (2002)
  •  New England Fertility Society (2002)
  • American Fertility Association (2005)
  • American Association of Bioanalysts (2005)
  • ALPHA Embryology Society (2010)

PUBLICATIONS

  1. Utilization of Clenbuterol Clorhidrate in Bovine Embryo Transfer, Argentinian Chamber of Biotechnology an Artificial Insemination, 1988
  2. Advantage of Measuring the Progesterone Levels in Donors of Embryo Transfers, pre Superovulation and Insemination, unpublished, 1989
  3. Use of Target P4 Kits Serono in Serum and Milk Samples of Recipients for Embryo Transfer, paper of the field trial results for Serono Italy/Argentina, 1989.
  4. Bovine Superovulation with HMG- Pergonal, paper of the field trial results for Serono Italy/Argentina, 1989.
  1. Improving the Semen Quality of Problem Bulls with HCG-Profasi, paper of the field trial results for Serono Italy/Argentina, 1989.
  2. Biotechnology Associated with Animal Reproduction, video produced
  3. together with Serono Argentina and paper presented in Limousin and
  4. Aberdeen Angus Magazines, Buenos Aires, Argentina, 1990.
  5. Superovulatory Response Using One or Two Daily Doses of Four Different Follicle Stimulating Hormones, American Embryo Transfer Newsletter, USA.
  6. Practice Tips in the American Embryo Transfer Newsletter, 1991.
  7. Antibiotic Intrauterine Infusion in Superovulated Donors as a way to Improve the Production of Viable Embryos, American Embryo Transfer Newsletter, USA, 1991.
  8. Direct Transfer Of Bovine Embryos, Aberdeen Angus and Polled Hereford Magazines, Buenos Aires, Argentina, 1996.
  9. Evaluation of the Efficiency of Embryo Transfer Programs, Aberdeen Angus and Polled Hereford Magazines, Buenos Aires, Argentina, 1997.
  10. Technical Bulletin for Serono Argentina promoting the use of FSH-Pluset Italy, 1997.
  11. Production of Viable Embryos with Dominant Follicle Remotion, Irac Meeting, Rosario, Argentina, 1999.
  12. Administration of a Prostaglandin Inhibitor at Embryo Transfer Improves Pregnancy Rates, International Embryo Transfer Association Meeting, USA.
  13. High Production of Viable Embryos per Superovulated Donor with FSH-Pluset Calier España, IRAC Meeting, Cordoba, Argentina, 2001.
  14. Use of Prostaglandin Inhibitors (Flunixin Meglumine-Schering) to Improve Pregnancy Rates in Recipients of Embryo Transfer, IRAC Meeting, Cordoba, Argentina, 2001.
  15. Premature Luteinization in GnRH-Antagonist Cycles in Patients with Polycystic Ovarian Syndrome and IVF Outcome, Segal, I. Glatstein, P. McShane, S. Hotamisligil, D. Ezcurra, R. Carson, ASRM 2004.
  1. A Standardized Protocol with Minimal Monitoring for Controlled Ovarian Stimulation of Egg Donors Results in Improved Pregnancy Rates, B. M. Berger, D. Ezcurra, M. M. Alper. ASRM 2004
  2. The Agonist-Antagonist Protocol: A Novel Protocol for Treating the Poor Responder,B. M. Berger, D. Ezcurra, M. M. Alper. ASRM 2004.
  3. An Embryo Quality Controlled Analysis of Pregnancy Rates After Embryo Transfer (ET), B. M. Berger, J. Witmyer, S. Wang, D. Ezcurra, M. M. Alper, ASRM 2004.
  4. Clinical Outcomes of IVF/ICSI Cycles Performed with Sperm Obtained via Epididymal Aspiration vs. Testicular Biopsy, S. Klipstein, D. Ezcurra, B. Miller, M. M. Alper, ASRM 2004.
  5. Paternal Age and Outcome in Egg Donation Cycles,S. Hotamisligil, R. Carson, D. Ezcurra, S. Pang. ASRM 2004.
  6. The Effect of the Starting Date of Controlled Ovarian Stimulation with Clomiphene Citrate on the Endometrial Thickness,S. Segal, C. Lyman, M. Wallace-Hall, D. Ezcurra, W. Gates, A. Mendel, ASRM 2004.
  7. Gonadotropin Releasing Hormone (GnRH) Antagonist (Cetrorelix) Versus GnRH agonist Treatment – an Age and Gonadotropin Matched Study in Young Normal Responders, B. M. Berger, D. Ezcurra, M. M. Alper, ASRM 2004.
  8. Comparison of In-Vitro Fertilization-Embryo Transfer (IVF-ET) Outcomes in Patients Treated with Recombinant Human Follicle Stimulating Hormone (r-hFSH) or r-hFSH and Human Menopausal Gonadotropins (hMG), B. M. Berger, D. Ezcurra, M. M. Alper, ASRM 2004.
  9. Deciding the Most Advantageous Controlled Ovarian Stimulation (COS) Protocol for Obtaining Better Outcomes: Pure Recombinant FSH (rFSH) or a Combination of rFSH and Human Menopausal Gonadotropin (hMG), T. Chapman, W. Caswell, N. E. Calvert, D. Ezcurra, M. Tucker, G. San Roman. ASRM 2004.
  10. Ectopic Pregnancy After Ultrasound Guided Intrauterine Embryo Transfer, an Analysis of Significant Clinical Variables, V. J. Paoletti-Falcone, D. Ezcurra, ASRM 2004.
  11. IVF Success Rates in Patients With an Elevated Baseline FSH (> 10 mIU/ml): Antagonist vs. Microdose Flare, Ryley DA, Ezcurra D, Von Wald T, Zimon A, Alper MM, Fertility and Sterilit, September 2005 (Vol. 84, Issue (Supplement 1), Pages S43-S44).
  12. 1477 Controlled Ovarian Stimulation (COH) Cycles Using Single Intra-uterine Insemination (SIUI) 36 Hours Post hCG Administration or Double (DIUI) 24-48 Hours After hCG: Are We Improving Pregnancy Outcome? Sulit MT, Baek K, Ezcurra D,  Rosenwaks Z, Fertility and SterilitySeptember 2005 (Vol. 84, Issue (Supplement 1), Page S66).
  13. Adding Morphologically Inferior Embryos to One or More Superior Embryos in ART Patients: Are We Improving Pregnancy Outcome? McShane P,  Ezcurra D, Carson R, Fertility and SterilitySeptember 2005 (Vol. 84, Issue (Supplement 1), Page S262).
  14. Reducing the Risk of Multiples While Maintaining Pregnancy Rates After Controlled Ovarian Hyperstimulation Intrauterine Insemination Cycles Baek K, Sulit M,Ezcurra D, Davis OK, Rosenwaks Z, Fertility and Sterility, September 2005 (Vol. 84, Issue Supplement 1), Page S276).
  15. IVF Outcomes in Patients Age 38 Years or Older With a Normal Basal FSH (≤10 mIU/ml) vs. an Elevated Basal FSH (>10 mIU/ml) Ryley DA, Ezcurra D, Von Wald T, Zimon A, Alper MM, Fertility and Sterility, September 2005 (Vol. 84, Issue (Supplement 1), Pages S299-S300)
  16. IVF Outcome Following Controlled Ovarian Hyperstimulation With Gonadotropin and GnRH-Antagonist in Patients With Different Infertility Etiologies, Segal S, Glatstein I, McShane P, Hotamisligil S, Ezcurra D, Carson R, Fertility and Sterilit, September 2005 (Vol. 84, Issue (Supplement 1), Page S302).
  17. Comparing the Efficacy of Recombinant Human Chorionic Gonadotropin (r-hCG) Versus Urinary hCG (u-hCG) in Achieving Final Follicular Maturation in Patients Undergoing Assisted Reproductive Technologies (ART), Ryley DA, Zimon A, Von Wald T, Ezcurra D, Alper MMFertility and Sterility, September 2005 (Vol. 84, Issue (Supplement 1), Page S309).
  18. Comparing Pregnancy Outcomes of PCOS Versus Non PCOS (Ovulation Enhanced) Patients Who Underwent Clomiphene Citratre/ Intra-Uterine Insemination Cycles, Sulit MT, Ezcurra D, Rosenwaks Z, Fertility and Sterilit, September 2005 (Vol. 84, Issue (Supplement 1), Pages S431-S432).
  19. Agonist down-regulation, microdose flare, and antagonist protocols and the role of estradiol supplementation in improving clinical pregnancy rates, Leondires MP, Moore ME, Ezcurra D, Mangieri RT, Richlin SS, Fertility and Sterilit, September 2006 (Vol. 86, Issue 3 (Supplement), Pages S71-S72).
  20. Comparing the efficacy of recombinant human chorionic gonadotropin (r-hCG) versus urinary hCG (u-hCG) in patients who underwent controlled ovarian hyperstimulation (COH)/IUI cycles, Sulit MT, Ezcurra D, Rosenwaks Z, Fertility and Sterility, September 2006 (Vol. 86, Issue 3 (Supplement), Pages S92-S93).
  21. IVF outcomes in women over age 40 years with an elevated cycle day 3 FSH (≥ 10 mIU/mL), Thornton K, Ryley D, Alper MM, Ezcurra D,Fertility and Sterility, September 2006 (Vol. 86, Issue 3 (Supplement), Page S141).
  22. Controlled ovarian stimulation (COH) in IVF cycles involving women over the age of 40 years: Comparing outcomes between protocols using LH add-back vs. r-FSH alone in cycles utilizing GnRH antagonists,Thornton K, Ryley D, Alper MM, Ezcurra D, Fertility and Sterility, September 2006 (Vol. 86, Issue 3 (Supplement), Pages S141-S142).
  23. Individual follicle irrigation in poor responders does not increase the quantity of mature oocytes retrieved, Richlin S, Ezcurra D, Mangieri R, Moore M, Leondires MP
    Fertility and Sterilit, September 2006 (Vol. 86, Issue 3 (Supplement), Pages S151-S152).
  24. Evaluation of the implantation and pregnancy rates by quality in single embryo transfer (SET) versus double embryo transfer (DET) when using frozen-thawed blastocysts: Are we improving the results when adding more embryos, Coste ET, Ezcurra D, Cain KE, Saketos M, Tucker MJ, San Roman GA, Fertility and Sterility, September 2006 (Vol. 86, Issue 3 (Supplement), Page S245.
  25. Survey of embryo quality assessment – from ART centers within the United States, Hubbard J, Ezcurra D, Briley G, Grotjan E, Schertz J, Basuray R
    Fertility and Sterility, September 2006 (Vol. 86, Issue 3 (Supplement), Page S258)
  26. Estradiol supplementation during the luteal phase in patients undergoing controlled ovarian stimulation for IVF improves clinical pregnancy rates, Leondires MP, Ezcurra D, Chi L, Mangieri R, Moore M, Richlin S, Fertility and Sterility, September 2006 (Vol. 86, Issue 3 (Supplement), Page S346).
  27. Outcomes of GnRH antagonist IVF cycles using LH supplementation for COH: FSH/rhLH vs. FSH/hMG, Thornton K, Alper MM, Ryley D, Ezcurra D, Fertility and Sterility, September 2006 (Vol. 86, Issue 3 (Supplement), Page S411).
  28. 1353 Controlled ovarian stimulation (COH)/ intrauterine insemination (IUI) cycles: Is there any correlation between the number of follicles >16mm and the serum estradiol level at the time of triggering in predicting pregnancy outcomes?, Sulit MT, Ezcurra D, Rosenwaks Z, Fertility and Sterility, September 2006 (Vol. 86, Issue 3 (Supplement), Page S413).
  29. Outcome in women < 35 years of age undergoing consecutive cycles of in vitro fertilization (IVF) using the gonadotropin-releasing hormone antagonist protocol, Segal S, Glatstein I, Lyman C, McShane P, Ezcurra D, Mendel A, Fertility and Sterility, September 2006 (Vol. 86, Issue 3 (Supplement), Page S417).
  30. Estrogen effect on endometrial thickness in controlled ovarian stimulation with clomiphene citrate, Segal S, Nugent D, Lyman C, Ezcurra D, Ahern J, Mendel A, Fertility and Sterilit, September 2006 (Vol. 86, Issue 3 (Supplement), Pages S418-S419).
  1. Contemporary genetic technologies and female reproduction, Evian Annual Reproduction (EVAR) Workshop Group 2010, Fauser BC, Diedrich K, Bouchard P, Domínguez F, Matzuk M, Franks S, Hamamah S, Simón C, Devroey P, Ezcurra D, Howles CM., Hum Reprod Update. 2011 Nov-Dec;17(6):829-47. Epub 2011 Sep 6.
  2. Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients, Bosch E, Ezcurra D., Reprod Biol Endocrinol. 2011 Jun 21;9:82.
  1.  Cancer and fertility: strategies to preserve fertility, Diedrich K, Fauser BC, Devroey P; Evian Annual Reproduction (EVAR) Workshop Group 2009, Reprod Biomed Online. 2011 Mar;22(3):232-48. Epub 2010 Nov 13. Review.
  1. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis, Lehert P, Schertz JC, Ezcurra D., Reprod Biol Endocrinol. 2010 Sep 16;8:112.
  2. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology, Tur-Kaspa I, Ezcurra D.,Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1323-36.
  3. The Human Oocyte Preservation Experience (HOPE) a phase IV, prospective, multicenter, observational oocyte cryopreservation registry, Ezcurra D, Rangnow J, Craig M, Schertz J.,Reprod Biol Endocrinol. 2009 May 27;7:53.
  4. The HOPE Registry: first US registry for oocyte cryopreservation, Ezcurra D, Rangnow J, Craig M, Schertz J., Reprod Biomed Online. 2008 Dec;17(6):743-4.
  5. Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats, Alper M, Meyer R, Dekkers C, Ezcurra D, Schertz J, Kelly E.,Reprod Biol Endocrinol. 2008 Jul 22;6:31.
  6. Premature luteinization and in vitro fertilization outcome in gonadotropin/gonadotropin-releasing hormone antagonist cycles in women with polycystic ovary syndrome, Segal S, Glatstein I, McShane P, Hotamisligil S, Ezcurra D, Carson R.,Fertil Steril. 2009 May;91(5):1755-9. Epub 2008 Apr 3.
  7. Human blastocyst morphological quality is significantly improved in embryos classified as fast on day 3 (>or=10 cells), bringing into question current embryological dogma, Luna M, Copperman AB, Duke M, Ezcurra D, Sandler B, Barritt J., Fertil Steril. 2008 Feb;89(2):358-63. Epub 2007 May 25.

TO BE UPDATE WITH 20 new publications done between 2007-2017